



TREATMENT OF THE SEASONAL SPREAD OF ARVI AMONG CHILDREN

Rakhimova Aziza Fakhriddinovna

raximovaaziza27@gmail.com

Bukhara University of Innovative Education and Medicine

✓ **Abstract:** Mostly children and people over 60 years of age fall ill - the so-called risk groups for the incidence of ARVI. Every adult suffers from influenza or other acute respiratory viral infections on average 2-4 times a year, a schoolchild - 4-5 times, a preschool child - 6 times, a child of the first year of life has from 2 to 12 episodes of acute respiratory viral infections. The polyetiology of ARVI pathogens and the variability of viruses involved in the epidemic process, complications after an illness, necessitate the search for new diagnostic methods and optimization of treatment and preventive measures.

Key words: *acute respiratory viral infections, influenza virus, prevention, antiviral drugs, complex drugs, treatment*

Introduction

Among acute respiratory viral infections, influenza is of particular epidemiological and social significance, characterized by high morbidity and mortality rates, as well as severe socio-economic consequences. A feature of the epidemic situation in recent years is the simultaneous circulation in the human population of several respiratory viruses: influenza A (H3N2 and H1N1) and B with the periodic predominance of one of them, adenoviruses, parainfluenza viruses and rhinoviruses, respiratory syncytial viruses, coronaviruses, etc. Influenza viruses have unique variability of the genome, allowing it to evade the human immune system, which, combined with aerogenic transmission of the pathogen in conditions of close contact and high population migration, contributes to the rapid spread of infection. Features of the biology of the virus and the epidemiology of influenza lead to its widespread distribution among the population. Over the past 10 years, there has been



a varying intensity of the influenza epidemic process - from seasonal epidemic surges to epidemics and pandemics.

Other ARVIs are more often caused by representatives of three families of RNA-containing viruses: paramyxoviruses (respiratory syncytial virus, human metapneumovirus, parainfluenza viruses types 1–4), coronaviruses (229E, OC43, NL63, HKUI) and picornaviruses (rhinoviruses), as well as representatives of two families of DNA viruses: adenoviruses (types B, C, E) and parvoviruses (human bocavirus) [5-7].

The nature and severity of clinical manifestations of influenza vary from mild to extremely severe and depend on the type of pathogen and the reaction of the patient's immune system (immune response). The frequency of hospitalization of children with influenza depends on age: the younger the child, the higher the risk of severe illness requiring treatment in a hospital setting. A number of authors [8-10] indicate that the hospitalization rate (per 10 thousand hospitalized) in the group of children from 6 months. up to 2 years old is 10.4, among children from 2 to 4 years old - 5.7. At the same time, in the age category 5–17 years old it decreased to 1.1.

Flu vaccination

Vaccination is an effective way to protect both children (over 2 years old) and adults from influenza. It is this disease that is most severe, accompanied by severe intoxication and can cause life-threatening complications [24-27]. Vaccines change each year to reflect the most common strains that season. Ideally, the vaccine should be given 1-2 months before the start of the annual outbreak, as the immune system needs time to produce antibodies. Before vaccination, you must contact your pediatrician so that he can examine the child and make sure there are no contraindications.

Preventing influenza and ARVI, especially during an epidemic, is not an easy task. However, if you accustom yourself and your children to a daily routine, proper microclimate in the premises, good and healthy nutrition, if you get vaccinations on time and do not forget about hygiene, the likelihood of illness will be much lower [28-30].



Treatment

In accordance with the WHO methodological recommendations for the treatment and prevention of influenza [31-33] and similar Russian documents [34-36], the use of antiviral drugs against influenza viruses or other acute respiratory viral infections should begin as early as possible, immediately after the appearance of influenza-like symptoms; one should not wait for laboratory results confirmation of the etiology of the disease [37]. Influenza illness can present with a range of symptoms, ranging from a mild upper respiratory tract infection to an acute, life-threatening illness. Knowledge of the main symptoms of diseases caused by various respiratory viruses is essential for a doctor. This is due to the fact that modern principles of treatment of ARVI, in addition to symptomatic drugs, include a wide range of etiotropic drugs, many of which have a selective effect against specific viruses, which must be taken into account when prescribing them [38-41].

Modern approaches to the treatment of ARVI, including influenza, include the use of both medicinal and non-medicinal methods (regime, hygiene, diet, sanitation of the upper respiratory tract, physiotherapy). The main goals of therapy for these infections are suppression of viral replication in the early stages of the disease, relief of clinical manifestations of viral infection, prevention and treatment of complications.

In recent years, in the treatment of ARVI and influenza, preference is given to drugs that have several points of application and have a combined effect, which combine direct antiviral, immunomodulatory and symptomatic effects. In situations with an unspecified pathogen and the absence of a laboratory-confirmed mixed viral infection, therapy with broad-spectrum antiviral drugs should be started.

Of great importance in the treatment of ARVI and influenza are drugs that can have an effect both on the infectious agent (specified or unspecified) and on the manifestations of the intoxication-inflammatory syndrome (fever, chills, pain, swelling, catarrhal phenomena). One of the broad-spectrum agents for nonspecific protection against influenza and other acute respiratory viral infections is enisamium iodide. Its action is based on direct inhibition of the process of viral penetration



through the cell membrane. The drug has interferonogenic properties, helps increase the concentration of endogenous interferon (alpha and gamma interferons) in the blood plasma by 3–4 times, increases the level of lysozyme, enhances the body's resistance to viral infections, reduces the clinical manifestations of viral intoxication, helps reduce the duration of the disease, provides anti-inflammatory, antipyretic and analgesic effect.

Conclusions

Influenza and other acute respiratory viral infections still remain one of the pressing medical and socio-economic problems, the solution of which is possible only at the state level.

Vaccination against influenza for groups at increased risk of infection has been introduced into the National Calendar of Preventive Vaccinations; work is underway to prepare for the widespread use of a new generation influenza vaccine that can mitigate the problem of variability of the influenza virus; A quadrivalent vaccine has been created.

New etiotropic drugs are constantly being developed and introduced into clinical practice that can quickly cure a patient from influenza and prevent the development of complications, which are the main cause of mortality in the unvaccinated population.

Among antiviral drugs that have a specific effect on specific proteins and key structures of the virus, preference is given to drugs that additionally affect the cellular and humoral immune mechanisms of antiviral defense.

REFERENCE:

1. Кильдиярова Рита Рафгатовна, Макарова Валерия Ивановна. Поликлиническая и неотложная педиатрия. Учебник. ГЭОТАР-Медиа, 2021г.
2. Курманова Ж.Т., Ермадиева Т.Ж., Коргамбаева Г.С., Абишева Н.А., Баяндинова А.А., Бердыханова Г.Т., Ягофаров Ф.Ф. Профилактика ОРВИ у детей в амбулаторно-поликлинических условиях // Наука и здравоохранение. 2013. №2.



3. Никитина Ирина Леоровна, Косенкова Тамара Васильевна, Новикова Валерия Павловна. Детские болезни. СпецЛит, 2021 г.
4. Геппе Наталья Анатольевна, Горелов Александр Васильевич, Лыскина Галина Афанасьевна. Детские болезни. Учебник. ГЭОТАР-Медиа, 2018 г.
5. Абдуллоевна, М. Ш. . (2024). БОЛАЛАРДА ЦИТОМЕГАЛОВИРУСЛИ ИНФЕКЦИЯ КЕЧИШИНИНГ КЛИНИКО-ИММУНОЛОГИК ХУСУСИЯТЛАРИ. *SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES*, 3(3), 32–36. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/9931>
6. Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. *SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES*, 2(12), 22–28. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678>
7. Ibrokhimovna, M. M. . (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. *Journal of Intellectual Property and Human Rights*, 3(4), 19–25. Retrieved from <http://journals.academiczone.net/index.php/jiphr/article/view/2506>
8. Abdulloeyevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. *SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES*, 2(12), 29–34. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680>
9. Yomgurova Ozoda Rajabturdievna. (2023). ALLERGIC REACTIONS AND MEDICINAL PRODUCTS: CONTEMPORARY PRESENTATIONS. *Galaxy International Interdisciplinary Research Journal*, 11(4), 818–823. Retrieved from <https://www.giirj.com/index.php/giirj/article/view/5080>
10. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitora Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. *Journal of Advanced Zoology*, 44(S2), 3744–3750. Retrieved from



<http://www.jazindia.com/index.php/jaz/article/view/1716>

11. Mukhammadieva M.I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Texas Journal of Medical Science. – 2022.- P. 86-90
12. Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. Texas Journal of Medical Science, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>
13. Abdulloev Mukhriddin Ziyodulloevich. (2023). Modern Therapy of Viral Hepatitis. Texas Journal of Medical Science, 26, 66–69. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4636>
14. Mukhammadieva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асоратланишининг профилактикаси ва давосини такомиллаштириш //Oriental Renaissance: Innovative, educational, natural and social sciences. -2023.-P.947-953.
15. Oblokulov A.R., M.I. Mukhammadieva. (2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis //Academicia Globe: Interdisciplinary Research. -2022.- P. 210-216.
16. M. R., M. ., & S. A., S. . (2022). Features of the Course of Contagious Giardiasis Associated with Giardiasis. Miasto Przyszłości, 26, 186–189. Retrieved from <https://miastoprzyszlosci.com.pl/index.php/mp/article/view/464>
17. Sanokulova Sitora Avazovna. (2023). COVID-19 IN CHILDREN. Academia Science Repository, 4(06), 25–32. Retrieved from <https://academiascience.com/index.php/repo/article/view/843>
18. Sanokulova Sitora Avazovna. (2023). Acute Kidney Injury in Critically Ill Cirrhotic Patients with Spontaneous Bacterial Peritonitis. Texas Journal of Medical Science, 25, 65–70. Retrieved from <https://zienjournals.com/index.php/tjms/article/view/4502>



19. Sanokulova Sitora Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. Texas Journal of Medical Science, 26, 4–9. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4611>
20. Авазовна, С. С. . (2023). Факторы Развития Гепаторенального Синдрома У Больных Циррозом Печени Вирусной Этиологии. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 1–8. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8673>
21. Санокуллова, Ситора Авазовна ОСОБЕННОСТИ ТЕЧЕНИЯ КОНТОГИОЗНЫХ ГЕЛЬМИНТОВ АССОЦИИРОВАННОГО С ЛЯМБЛИОЗОМ // ORIENSS. 2023. №2. URL: <https://cyberleninka.ru/article/n/ocobennosti-techeniya-kontogioznyh-gelmintov-assotsirovannogo-s-lyambliozom> (дата обращения: 12.12.2023).
22. Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. Oriental renaissance: Innovative, educational, natural and social sciences, 2 (6), 253-257.\
29. A. A., E., A. S., D., & A., M. S. (2022). Modern Approaches to Treatment of Chronic Giardiasis. Central Asian Journal of Medical and Natural Science, 3(2), 102-105. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/631>
23. Облокулов, А., & Мухаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИИ. Журнал вестник врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016
24. Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. Central Asian Journal of Medical and Natural Science, 3(3), 438-443. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806>



25. Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES. – 2022.- P. 9-12.
26. Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(1), 41-44.
27. Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // International journal of medical sciences and clinical research 2022;17-21.
28. Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. International Journal of Medical Sciences And Clinical Research, 2(09), 12–16.
<https://doi.org/10.37547/ijmscr/Volume02Issue09-04>
29. Raximovich, O. A., Sadilloevna, J. A., Abdulloevna, M. S., & Farxodovich , R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294.
<https://doi.org/10.17605/OSF.IO/9CFP6>
30. Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии //CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 81-86.
31. Abdulloevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 29–34. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680>
32. Muxtorova, S. A. (2022). Clinical and laboratoriya features of acute respiratory disease in frequently ill children. Web of scientist: International scientific research journal, 1026-1030.



33. Mukhtarova, S. H. (2022). A.(2022) AGE-RELATED FEATURES OF CLINICAL MANIFESTATIONS OF GIARDIASIS. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 17-21.
34. Mukhtorova Shokhida Abdulloevna. (2023). Microbiological Indicators of Patients Infected with SarsCov-2. Texas Journal of Medical Science, 21, 41–45. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4116>
35. Mukhtorova Shokhida Abdulloevna. (2023). CYTOMEGALOVIRUS INFECTIONS IN CHILDREN WITH PRIMARY AND SECONDARY IMMUNE DEFICIENCIES. Academia Science Repository, 4(06), 23–28. Retrieved from <http://academiascience.com/index.php/repo/article/view/832>
36. Aslonova.M.R. (2023). VITAMIN DEFICIENCY CASES RESULTING FROM PARASITIC DISEASES // Galaxy International Interdisciplinary Research Journal.- 2023.-P. 404-409
37. Mukhtorova Shokhida Abdulloevna. (2023). CHARACTERISTIC FEATURES OF THE COURSE OF CITOMEGALOVIRUS INFECTION IN CHILDREN. Galaxy International Interdisciplinary Research Journal, 11(4), 484–487. Retrieved from <https://giirj.com/index.php/giirj/article/view/5150..>
38. Raximovich, O. A., Sadilloevna, J. A., Abdulloevna, M. S., & Farxodovich, R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. *Central Asian Journal of Medical and Natural Science*, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>
39. Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 22–28. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678>